Shire neurology, dermatology news
Shire disclosed its 1Q12 earnings two legal investigations related to ADHD drugs Adderall XR amphetamine and Vyvanse lisdexamfetamine and to diabetic foot ulcer therapy Dermagraft. On April 5, it received a Civil Investigative Demand (CID) from the U.S. Federal Trade Commission (FTC) requesting the company provide information about the supply and reported shortages of Adderall XR and its authorized generics. The FTC also asked for information about the marketing of Adderall XR, its authorized generics and Shire's Vyvanse. Shire said it believes the CID was triggered by reports of shortages of the drugs last year. The company said it is cooperating with the FTC.
Shire also said the Department of Justice and the U.S. Attorney's Offices for the Middle District of Florida and for Washington D.C. are conducting civil and criminal investigations into the sales and marketing practices for Dermagraft, which Shire's Advanced BioHealing Inc. unit markets in the U.S. ...